Ornament2.png

Epodion

Treatment of anaemia associated with chronic renal failure in adult patients on haemodialysis and peritoneal dialysis.

Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.

Short Description

EPODION has recombinant human erythropoietin alfa (INN; Epoetin alfa) as an active ingredient, that is a single chain glycoprotein composed of 165 amino acids, and its molecular weight is 26-30 kDa with glycosylation.Epoetin alfa obtained by gene technology is identical in its amino acid sequence to erythropoietin that has been isolated from the urine of anaemic patients.

Generally human erythropoietin is produced in fibroblastoid interstitial cells in the kidneys and liver and then travels to the bone marrow to stimulate red blood cell production. Due to this nature of human erythropoietin, indication of Epoetin alfa is hormone-replacement therapy in the anemia.

Indications

Treatment of anaemia associated with chronic renal failure in adult patients on haemodialysis and peritoneal dialysis.

Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.

Specification

Injection

Epodion® 2000 IU/0.5 mL

  • Each PFS (Pre-Filled Syringe) contain Recombinant Human Erythropoietin Alfa 2000iu

  • Box, 6 PFS @ 2000 IU/0.5 mL

Epodion® 3000 IU/0.3 mL

  • Each PFS (Pre-Filled Syringe) contain Recombinant Human Erythropoietin Alfa 3000iu

  • Box, 6 PFS @ 3000 IU /0.3 mL

Epodion® 4000 IU/0.4 mL

  • Each PFS (Pre-Filled Syringe) contain Recombinant Human Erythropoietin Alfa 4000 IU

  • Box, 6 PFS @ 4000iu/ 0.4 mL

Epodion® 10.000 IU/ mL

  • Each PFS (Pre-Filled Syringe) contain Recombinant Human Erythropoietin Alfa 10.000 IU

  • Box, 6 PFS @ 10.000iu/ 1 mL

multi-gyn.png

Cardiovascular & Hematopoietic Systems Product